Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis

THOMSON REUTERS
09 Apr

Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose Lumina Trial of Amx0114 in People Living With Amyotrophic Lateral Sclerosis

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10